MedPacto (235980.KQ) Action Cours

MedPacto Inc. generates revenue through the research and development of anti-cancer drugs and diagnostic kits. The company develops products such as vactosertib and MA-B2, which are used to treat multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer, and pancreatic cancer. These products are targeted at medical professionals and healthcare institutions seeking advanced treatment options for various cancer types. The company focuses on oncology solutions, serving the healthcare segment with its specialized drug portfolio. MedPacto Inc. operates in the pharmaceutical sector with a clear focus on developing innovative treatments for multiple cancer indications. The firm's product lineup includes vactosertib and MA-B2, which are positioned for use in treating specific cancers like multiple myeloma and triple negative breast cancer. The company's business model relies on the development and commercialization of these targeted therapies, which are sold to hospitals and clinics specializing in cancer care. The revenue stream is derived from the sale of these prescription drugs and diagnostic kits to healthcare providers in the oncology field.